Overcoming Acquired Resistance With Second-Generation TRK Inhibitors

11/09/21 • 13 min

In this podcast episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss emerging data on the efficacy, safety, and clinical role of second-generation TRK inhibitors that can overcome acquired resistance to first-generation agents in NTRK fusion–positive solid tumors. Topics include:

Mechanisms of acquired resistance to TRK inhibitor therapy
Clinical trial data on the second-generation inhibitors selitrectinib and repotrectinib
Safety profiles of first- vs second-generation TRK inhibitors

Presenters:

George D. Demetri, MD
Professor of Medicine
Harvard Medical School
Harvard University
Co-Director, Ludwig Center at Harvard
Senior Vice President for Experimental Therapeutics
Director, Sarcoma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Alexander Drilon, MD
Chief, Early Drug Development
Attending, Thoracic
Memorial Sloan Kettering Cancer Center
New York, New York

Link to full program, including downloadable slides:
https://bit.ly/2YFIPfr

Mechanisms of acquired resistance to TRK inhibitor therapy
Clinical trial data on the second-generation inhibitors selitrectinib and repotrectinib
Safety profiles of first- vs second-generation TRK inhibitors

Presenters:

Alexander Drilon, MD
Chief, Early Drug Development
Attending, Thoracic
Memorial Sloan Kettering Cancer Center
New York, New York

Link to full program, including downloadable slides:
https://bit.ly/2YFIPfr

Previous Episode

Role of TKIs in Nonadipocytic Soft Tissue Sarcoma and Advanced Osteosarcoma

In this podcast episode, Jean-Yves Blay, MD, PhD, and Robin L. Jones, BSc, MBBS, MRCP, MD(Res), discuss the most important clinical trial data on leveraging TKIs as monotherapy and in combination with chemotherapy or immune checkpoint inhibitors for treatment of soft tissue sarcoma and osteosarcoma.

Presenters:

Jean-Yves Blay, MD, PhD
Professor of Medical Oncology
Department of Medicine
Centre Leon Berard
Lyon, France

Robin L. Jones, BSc, MBBS, MRCP, MD(Res)
Professor
Sarcoma Unit
Royal Marsden Hospital and Institute of Cancer Research
London, United Kingdom

Link to full program, including accompanying downloadable slidesets:
https://bit.ly/2ZL9bxq

Next Episode

Experts Answer FAQs on Immunotherapy for Non-Small-Cell Lung Cancer

In this podcast episode, Julie Brahmer, MD, MSc, and Jarushka Naidoo, MB BCH BAO, MHS, answer audience questions from a live CCO webinar on evolving immunotherapy strategies for NSCLC, with topics including:

Patient and/or disease-related factors considered when choosing first-line immunotherapy-based regimens
Second-line therapeutic options after disease progression on an immunotherapy-based regimen
Immunotherapy in patients with advanced NSCLC and brain metastases
Distinguishing between immunotherapy-induced and radiation-induced pneumonitis, with expert perspective on rebiopsy
Future directions in immunotherapy for NSCLC, including the role of the gut microbiome in response

Presenters:

Julie Brahmer, MD, MSc
Professor of Oncology
Director, Thoracic Oncology
Co-Director, Upper Aerodigestive Cancer Program
Bloomberg-Kimmel Institute for Cancer Immunology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins Medicine
Baltimore, Maryland

Jarushka Naidoo, MB BCH BAO, MHS
Consultant Medical Oncologist
Beaumont Hospital/RCSI University of Health Sciences
Dublin, Ireland
Adjunct Assistant Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

Content based on an online CME program supported by educational grants from Bristol-Myers Squibb; Genentech, a member of the Roche Group; Helsinn Healthcare SA; and Merck Sharp & Dohme Corp.

Follow along with the PDF:
https://bit.ly/31aRRmd

Link to full program:
https://bit.ly/3CLC0Hd